Institut National De La Sante Et De La Recherche Medicale

Innavirvax

Assistance Publique-hopitaux De Paris

Inserm

Minka Therapeutics

Vincent Vieillard

Joël Crouzet

Patrice Debre

Laurence Meyer

The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID No 1], wherein Nt consists of a peptide having from 0 to 50 amino acids in length, Ct consists of a peptide having from 0 to 50 amino acids in length, each of X1 to X4 consists of an amino acid residue, wherein: (i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, (i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, (i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, (i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in its meaning (i), for preventing and/or treating an infection of an individual with an HIV-1 virus.

Compositions for preventing and/or treating an infection by an HIV-1 virus

The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID No 1], wherein &#x2014;Nt consists of a peptide having from 0 to 50 amino acids in length, &#x2014;Ct consists of a peptide having from 0 to 50 amino acids in length, &#x2014;each of X1 to X4 consists of an amino acid residue, wherein: &#x2014;(i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, &#x2014;(i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, &#x2014;(i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, &#x2014;(i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that &#x2014;three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and &#x2014;the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in its meaning (i), for preventing and/or treating an infection of an individual with an HIV-1 virus.

The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID No 1], wherein&#x2014;Nt consists of a peptide having from 0 to 50 amino acids in length, &#x2014;Ct consists of a peptide having from 0 to 50 amino acids in length, &#x2014;each of X1 to X4 consists of an amino acid residue, wherein: &#x2014;(i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, &#x2014;(i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, &#x2014;(i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, &#x2014;(i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that&#x2014;three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and&#x2014;the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in its meaning (i), for preventing and/or treating an infection of an individual with an HIV-1 virus.

Growing community of inventors

Paris, France

Vincent Vieillard